SRPT — Sarepta Therapeutics Inc USA
[[ lastPrice | number : 2]]
[[ refundPrice | number : 2]]
[[ refundPriceP | number : 2]]%
[[ refundPriceP | number : 2]]%
[[ lastDate * 1000 | date:'MMM d, y @h:mm a' ]]
Currency in USD
Currency in USD
UB Rating 1.5/5 Moderate Sell
Basic
Not enough data for Expected Return.
Not enough data for Risks (Volatility).
Not enough data for Beta calculations.
Market capital
$6.84B
Employees
866
Money
Not enough data for Earnings per share statistics.
Not enough data for Book Value calculations.
Wall Street price
$123.39
PE Ratio
—
Dividends
—
Volume & Social
Short Ratio
4.61%
Daily Volume
1.07M
Volume
Average
Social Rate
Untracked
Social Volume
Untracked
Latest SRPT news
[[ item.source ]]
-
[[ item.pubDate | date:'MMM d, y @ h:mma' ]]
[[ item.description ]]
Invest ideas
5 ideas for sell
58.00%
Fundamental signal
Short Interest Ratio is higher than industry.
Invest Ideas — the best way to get insights based on both fundamental and technical data.
We analyze company's performance across sector and industry and generate investing ideas for you.
Want to track signal changes?
It's easy to monitor changes in signal with our
watchlist. Just add the stock to your watchlist
and get daily, weekly and monthly signal changes for the asset.
Most and less correlated stocks. All correllations are calculated for 1 year period.
Learn more
about correlations.
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Revenue | |
| Total Revenue | [[fin.totalRevenue / 1000 | number : 0]] |
| Cost of Revenue | [[fin.costOfRevenue / 1000 | number : 0]] |
| Gross Profit | [[fin.grossProfit / 1000 | number : 0]] |
| Operating Expenses | |
| Research Development | [[fin.researchDevelopment / 1000 | number : 0]] |
| Selling General and Administrative | [[fin.sellingGeneralAdministrative / 1000 | number : 0]] |
| Non Recurring | [[fin.nonRecurring / 1000 | number : 0]] |
| Others | [[fin.otherOperatingExpenses / 1000 | number : 0]] |
| Total Operating Expenses | [[fin.totalOperatingExpenses / 1000 | number : 0]] |
| Operating Income or Loss | [[fin.operatingIncome / 1000 | number : 0]] |
| Income from Continuing Operations | |
| Total Other Income/Expenses Net | [[fin.totalOtherIncomeExpenseNet / 1000 | number : 0]] |
| Earnings Before Interest and Taxes | [[fin.ebit / 1000 | number : 0]] |
| Interest Expense | [[fin.interestExpense / 1000 | number : 0]] |
| Income Before Tax | [[fin.incomeBeforeTax / 1000 | number : 0]] |
| Income Tax Expense | [[fin.incomeTaxExpense / 1000 | number : 0]] |
| Minority Interest | [[fin.minorityInterest / 1000 | number : 0]] |
| Net Income From Continuing Ops | [[fin.netIncomeFromContinuingOps / 1000 | number : 0]] |
| Non-recurring Events | |
| Discontinued Operations | [[fin.discontinuedOperations / 1000 | number : 0]] |
| Extraordinary Items | [[fin.extraordinaryItems / 1000 | number : 0]] |
| Effect Of Accounting Changes | [[fin.effectOfAccountingCharges / 1000 | number : 0]] |
| Other Items | [[fin.otherItems / 1000 | number : 0]] |
| Net Income | |
| Net Income | [[fin.netIncome / 1000 | number : 0]] |
| Net Income Applicable To Common Shares | [[fin.netIncomeApplicableToCommonShares / 1000 | number : 0]] |
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Current Assets | |
| Cash And Cash Equivalents | [[fin.cash / 1000 | number : 0]] |
| Short Term Investments | [[fin.shortTermInvestments / 1000 | number : 0]] |
| Net Receivables | [[fin.netReceivables/ 1000 | number : 0]] |
| Inventory | [[fin.inventory/ 1000 | number : 0]] |
| Other Current Assets | [[fin.otherCurrentAssets/ 1000 | number : 0]] |
| Total Current Assets | [[fin.totalCurrentAssets / 1000 | number : 0]] |
| Long Term Investments | [[fin.longTermInvestments / 1000 | number : 0]] |
| Property Plant and Equipment | [[fin.propertyPlantEquipment / 1000 | number : 0]] |
| Goodwill | [[fin.goodWill / 1000 | number : 0]] |
| Intangible Assets | [[fin.intangibleAssets / 1000 | number : 0]] |
| Other Assets | [[fin.otherAssets / 1000 | number : 0]] |
| Total Assets | [[fin.totalAssets / 1000 | number : 0]] |
| Current Liabilities | |
| Accounts Payable | [[fin.accountsPayable / 1000 | number : 0]] |
| Short/Current Long Term Debt | [[fin.shortLongTermDebt / 1000 | number : 0]] |
| Other Current Liabilities | [[fin.otherCurrentLiab / 1000 | number : 0]] |
| Total Current Liabilities | [[fin.totalCurrentLiabilities / 1000 | number : 0]] |
| Long Term Debt | [[fin.longTermDebt / 1000 | number : 0]] |
| Other Liabilities | [[fin.otherLiab / 1000 | number : 0]] |
| Deferred Long Term Liability Charges | [[fin.deferredLongTermLiab / 1000 | number : 0]] |
| Total Liabilities | [[fin.totalLiab / 1000 | number : 0]] |
| Stockholders' Equity | |
| Common Stock | [[fin.commonStock / 1000 | number : 0]] |
| Retained Earnings | [[fin.retainedEarnings / 1000 | number : 0]] |
| Other Stockholder Equity | [[fin.otherStockholderEquity / 1000 | number : 0]] |
| Total Stockholder Equity | [[fin.totalStockholderEquity / 1000 | number : 0]] |
| Net Tangible Assets | [[fin.netTangibleAssets / 1000 | number : 0]] |
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Net Income | [[fin.netIncome/ 1000 | number : 0]] |
| Operating Activities, Cash Flows Provided By or Used In | |
| Depreciation | [[fin.depreciation / 1000 | number : 0]] |
| Adjustments To Net Income | [[fin.changeToNetincome / 1000 | number : 0]] |
| Changes In Accounts Receivables | [[fin.changeToAccountReceivables / 1000 | number : 0]] |
| Changes In Liabilities | [[fin.changeToLiabilities / 1000 | number : 0]] |
| Changes In Inventories | [[fin.changeToInventory / 1000 | number : 0]] |
| Changes In Other Operating Activities | [[fin.changeToOperatingActivities / 1000 | number : 0]] |
| Total Cash Flow From Operating Activities | [[fin.totalCashFromOperatingActivities / 1000 | number : 0]] |
| Investing Activities, Cash Flows Provided By or Used In | |
| Capital Expenditures | [[fin.capitalExpenditures / 1000 | number : 0]] |
| Investments | [[fin.investments / 1000 | number : 0]] |
| Other Cash flows from Investing Activities | [[fin.otherCashflowsFromInvestingActivities / 1000 | number : 0]] |
| Total Cash Flows From Investing Activities | [[fin.totalCashflowsFromInvestingActivities / 1000 | number : 0]] |
| Financing Activities, Cash Flows Provided By or Used In | |
| Dividends Paid | [[fin.dividendsPaid / 1000 | number : 0]] |
| Sale Purchase of Stock | [[fin.salePurchaseOfStock / 1000 | number : 0]] |
| Net Borrowings | [[fin.netBorrowings / 1000 | number : 0]] |
| Other Cash Flows from Financing Activities | [[fin.otherCashflowsFromFinancingActivities / 1000 | number : 0]] |
| Total Cash Flows From Financing Activities | [[fin.totalCashFromFinancingActivities / 1000 | number : 0]] |
| Change In Cash and Cash Equivalents | [[fin.changeInCash / 1000 | number : 0]] |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
| Avg | -1.14 | -1.40 | -4.95 | -4.47 |
| High | -0.28 | -0.58 | -4.01 | 1.65 |
| Low | -1.99 | -2.30 | -6.29 | -8.07 |
| Avg | 197M | 196M | 688M | 896M |
| High | 204M | 218M | 704M | 1.36B |
| Low | 182M | 150M | 613M | 734M |
| [[fin.date | strtotimestamp | date: 'MMM d,yyyy']] | |
| Earnings History | |
| Earnings Actual | [[fin.epsActual | number : 2]] |
| Earnings Estimate | [[fin.epsEstimate | number : 2]] |
| Difference | [[fin.epsDifference | number : 2]] |
| Surprise | [[fin.surprisePercent | number : 1]]% |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| Earnings Estimate | ||||
| Number of Analysts | [[financials['etrend']['0q'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1q'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['0y'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1y'].earningsEstimateNumberOfAnalysts | number : 0]] |
| Estimate Average | [[financials['etrend']['0q'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['0y'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateAvg | number : 2]] |
| Estimate High | [[financials['etrend']['0q'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['0y'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateHigh | number : 2]] |
| Estimate Low | [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] | [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] | [[financials['etrend']['0y'].earningsEstimateLow | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateLow | number : 2]] |
| Estimate Growth | [[financials['etrend']['0q'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['0y'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateGrowth | number : 2]] |
| Year Ago EPS | [[financials['etrend']['0q'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['0y'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateYearAgoEps | number : 2]] |
| All numbers in thousands (except analysts) | Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) |
| Revenue Estimate | ||||
| Number of Analysts | [[financials['etrend']['0q'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['0y'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateNumberOfAnalysts | number : 0]] |
| Estimate Average | [[financials['etrend']['0q'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateAvg / 1000 | number : 0]] |
| Estimate High | [[financials['etrend']['0q'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateHigh / 1000 | number : 0]] |
| Estimate Low | [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateLow / 1000 | number : 0]] |
| Estimate Growth | [[financials['etrend']['0q'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['+1q'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['0y'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['+1y'].revenueEstimateGrowth * 100| number : 2]]% |
| Year Ago EPS | [[financials['etrend']['0q'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['0y'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateYearAgoEps | number : 0]] |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| EPS Trend | ||||
| Current Estimate | [[financials['etrend']['0q'].epsTrendCurrent | number : 2]] | [[financials['etrend']['+1q'].epsTrendCurrent | number : 2]] | [[financials['etrend']['0y'].epsTrendCurrent | number : 2]] | [[financials['etrend']['+1y'].epsTrendCurrent | number : 2]] |
| 7 Days Ago | [[financials['etrend']['0q'].epsTrend7daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend7daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend7daysAgo| number : 2]] | [[financials['etrend']['+1y'].epsTrend7daysAgo | number : 2]] |
| 30 Days Ago | [[financials['etrend']['0q'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend30daysAgo | number : 2]] |
| 60 Days Ago | [[financials['etrend']['0q'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend60daysAgo | number : 2]] |
| 90 Days Ago | [[financials['etrend']['0q'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend90daysAgo | number : 2]] |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| EPS Revisions | ||||
| Up Last 7 Days | [[financials['etrend']['0q'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsUpLast7days | number : 0]] |
| Up Last 30 Days | [[financials['etrend']['0q'].epsRevisionsUpLast30days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsUpLast30days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsUpLast30days| number : 0]] | [[financials['etrend']['+1y'].epsRevisionsUpLast30days | number : 0]] |
| Down Last 30 Days | [[financials['etrend']['0q'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsDownLast7days | number : 0]] |
| Down Last 90 Days | [[financials['etrend']['0q'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsDownLast30days | number : 0]] |